| Literature DB >> 24406785 |
Thoraya A Farghaly1, Eman M H Abbas2, Kamal M Dawood3, Tarek B A El-Naggar4.
Abstract
Two series of naphtho[1,8-ef][1,4]diazepines andEntities:
Mesh:
Substances:
Year: 2014 PMID: 24406785 PMCID: PMC6271148 DOI: 10.3390/molecules19010740
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Reaction of 1,8-diaminonaphthalene (1) with hydrazonoyl chlorides 2 and 4.
UV Spectral data of compounds 3a–j, 5a,b and 11a–h in dioxane.
| Compd. No. | λmax (log ε) | Compd. No. | λmax (log ε) |
|---|---|---|---|
|
| 359 (4.25) |
| 378 (4.45) |
|
| 349 (3.89) |
| 385 (4.33) |
|
| 347 (3.59) |
| 484 (4.24), 346 (4.19), 269 (4.24) |
| 348 (4.30) |
| 476 (4.01), 340 (4.10), 233 (4.28) | |
|
| 349 (3.87) | 473 (4.15), 351 (4.32), 231 (4.38) | |
|
| 349 (3.88) |
| 472 (4.24), 339 (4.15), 232 (4.35) |
|
| 345 (3.89) |
| 472 (4.0), 337 (3.89), 267 (4.01) |
|
| 381 (3.76) |
| 490 (4.66), 357 (4.57), 231 (4.89) |
|
| 359 (4.19) |
| 509 (4.05), 361 (4.11), 262 (4.13) |
|
| 351 (4.05) |
| 478 (4.10), 336 (3.79), 296 (3.80) |
* Solvent λmax (log ε): acetone: 349 (4.01); chloroform: 348 (4.02); cyclohexane: 347 (4.11); ethanol 348 (4.04); DMF 349 (4.24); ** Solvent λmax (log ε): acetone: 473 (4.20), 350 (4.35), 231 (4.41); chloroform: 473 (3.99), 353 (4.15), 233 (4.28); cyclohexane: 473 (4.25), 350 (4.10), 230 (4.08); ethanol 472 (4.24), 352 (4.23), 236 (4.47); DMF 476 (4.36), 346 (4.29), 231 (4.38).
Scheme 2Reaction of 1,8-diaminonaphthalene (1) with 4-hydroxycoumarin (6).
Scheme 3Reaction of compound 8 with hydrazonoyl chlorides 4a–h.
Scheme 4The mechanism of formation of compounds 11.
Figure 1Tautomeric structures of compounds 11.
Concentration (µM/mL) required to inhibit cell growth by 50% (GI50), to produce total growth inhibition (TGI) and to cause 50% net cell killing (LC50).
| Product | Inhibition parameters | TK-10 | MCF-7 | UACC-62 |
|---|---|---|---|---|
|
| GI50 | 62.44 ± 3.58 | 80.66 ± 5.24 | >100 |
| TGI | >100 | >100 | >100 | |
| LC50 | >100 | >100 | >100 | |
|
| GI50 | >100 | 95.48 ± 11.62 | >100 |
| TGI | >100 | >100 | >100 | |
| LC50 | >100 | >100 | >100 | |
|
| GI50 | 83.72 ± 9.73 | >100 | >100 |
| TGI | >100 | >100 | >100 | |
| LC50 | >100 | >100 | >100 | |
|
| GI50 | 96.73 ± 11.27 | 81.29 ± 8.28 | 41.97 ± 4.97 |
| TGI | >100 | >100 | 86.66 ± 7.14 | |
| LC50 | >100 | >100 | >100 | |
|
| GI50 | 71.06 ± 4.87 | 63.87 ± 3.49 | >100 |
| TGI | >100 | >100 | >100 | |
| LC50 | >100 | >100 | >100 | |
|
| GI50 | 72.08 ± 6.94 | 42.25 ± 4.11 | >100 |
| TGI | >100 | >100 | >100 | |
| LC50 | >100 | >100 | >100 | |
|
| GI50 | 16.39 ± 1.79 | 12.67 ± 1.08 | 43.78 ± 1.05 |
| TGI | 25.28 ± 2.39 | 21.87 ± 2.10 | >100 | |
| LC50 | 38.99 ± 3.01 | 37.77 ± 3.91 | >100 |
The range of doses assayed was 0.01–100 µM/mL; Results are mean ± SE (standard error of the mean)
(n = 3); The GI50, TGI and LC50 for the other products are >100.
ORAC values for antioxidant activity of compounds 3, 8, and 11.
| Comp. No. | ORAC Value | Comp. No. | ORAC Value |
|---|---|---|---|
|
| 0.61 ± 0.04 |
| 0.86 ± 0.09 |
|
| 0.74 ± 0.07 |
| 0.43 ± 0.59 |
|
| 0.54 ± 0.06 |
| 0.51 ± 0.10 |
|
| 0.97 ± 0.10 |
| 0.60 ± 0.07 |
|
| 0.68 ± 0.03 |
| 0.62 ± 0.09 |
|
| 0.81 ± 0.05 |
| 0.42 ± 0.05 |
|
| 0.65 ± 0.07 |
| 0.53 ± 0.08 |
|
| 0.72 ± 0.06 |
| 0.59 ± 0.06 |
Data expressed as mean ± SE (standard error of the mean) (n = 3), and ORAC values expressed as µM of Trolox/mg sample.